Baker BROS. Advisors LP Has $19.62 Million Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Baker BROS. Advisors LP grew its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 123.4% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,227,178 shares of the company's stock after buying an additional 677,966 shares during the period. Baker BROS. Advisors LP owned approximately 1.08% of Centessa Pharmaceuticals worth $19,623,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in CNTA. First Light Asset Management LLC raised its position in shares of Centessa Pharmaceuticals by 59.2% during the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company's stock valued at $43,168,000 after buying an additional 1,778,515 shares during the last quarter. Farallon Capital Management LLC raised its position in shares of Centessa Pharmaceuticals by 438.0% during the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company's stock valued at $18,024,000 after buying an additional 1,625,000 shares during the last quarter. Driehaus Capital Management LLC raised its position in shares of Centessa Pharmaceuticals by 89.5% during the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company's stock valued at $18,891,000 after buying an additional 987,997 shares during the last quarter. Perceptive Advisors LLC raised its position in shares of Centessa Pharmaceuticals by 27.6% during the second quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company's stock valued at $35,518,000 after buying an additional 850,000 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new stake in Centessa Pharmaceuticals in the second quarter valued at about $4,064,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 16,619 shares of the stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $15.69, for a total value of $260,752.11. Following the sale, the insider now directly owns 206,750 shares in the company, valued at approximately $3,243,907.50. This trade represents a 7.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Saurabh Saha sold 175,000 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total transaction of $2,891,000.00. Following the completion of the sale, the chief executive officer now owns 776,924 shares in the company, valued at approximately $12,834,784.48. This trade represents a 18.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 375,128 shares of company stock worth $6,148,522 over the last ninety days. Company insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Price Performance

Shares of CNTA traded down $0.96 during mid-day trading on Monday, hitting $16.95. 384,610 shares of the company traded hands, compared to its average volume of 416,989. Centessa Pharmaceuticals plc has a one year low of $6.15 and a one year high of $18.74. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The business has a 50-day moving average of $16.22 and a 200 day moving average of $12.72. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of -11.52 and a beta of 1.47.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. As a group, equities analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on CNTA. Guggenheim upped their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Friday, November 15th. Jefferies Financial Group upped their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. BMO Capital Markets upped their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a research note on Monday, September 16th. Oppenheimer reaffirmed an "outperform" rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Finally, Morgan Stanley raised shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals has an average rating of "Buy" and an average target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.